160 related articles for article (PubMed ID: 30836453)
1. Beta
Hostrup M; Narkowicz CK; Habib S; Nichols DS; Jacobson GA
Drug Test Anal; 2019 Jul; 11(7):1048-1056. PubMed ID: 30836453
[TBL] [Abstract][Full Text] [Related]
2. Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Walters EH
Drug Test Anal; 2019 Jul; 11(7):950-956. PubMed ID: 30865387
[TBL] [Abstract][Full Text] [Related]
3. Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Haydn Walters E
Drug Test Anal; 2017 Aug; 9(8):1262-1266. PubMed ID: 28033454
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.
Lecaillon JB; Kaiser G; Palmisano M; Morgan J; Della Cioppa G
Eur J Clin Pharmacol; 1999 Apr; 55(2):131-8. PubMed ID: 10335908
[TBL] [Abstract][Full Text] [Related]
5. Beta
Onslev J; Jacobson G; Narkowicz C; Backer V; Kalsen A; Kreiberg M; Jessen S; Bangsbo J; Hostrup M
Eur J Appl Physiol; 2017 Sep; 117(9):1907-1915. PubMed ID: 28702809
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
[TBL] [Abstract][Full Text] [Related]
7. Enantioselective disposition of (R/S)-albuterol in skeletal and cardiac muscle.
Jacobson GA; Yee KC; Premilovac D; Rattigan S
Drug Test Anal; 2014 Jun; 6(6):563-7. PubMed ID: 24574331
[TBL] [Abstract][Full Text] [Related]
8. Beta
Hostrup M; Reitelseder S; Jessen S; Kalsen A; Nyberg M; Egelund J; Kreiberg M; Kristensen CM; Thomassen M; Pilegaard H; Backer V; Jacobson GA; Holm L; Bangsbo J
J Physiol; 2018 Sep; 596(17):4121-4139. PubMed ID: 29968301
[TBL] [Abstract][Full Text] [Related]
9. Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol.
Ganapathy V; Stensland MD
Int J Chron Obstruct Pulmon Dis; 2017; 12():1793-1801. PubMed ID: 28694692
[TBL] [Abstract][Full Text] [Related]
10. Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor--regulation and bronchodilatation.
Aziz I; McFarlane LC; Lipworth BJ
Eur J Clin Pharmacol; 1999 Aug; 55(6):431-6. PubMed ID: 10492055
[TBL] [Abstract][Full Text] [Related]
11. β
Scholpa NE; Simmons EC; Tilley DG; Schnellmann RG
Exp Neurol; 2019 Dec; 322():113064. PubMed ID: 31525347
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
Kharidia J; Fogarty CM; Laforce CF; Maier G; Hsu R; Dunnington KM; Curry L; Baumgartner RA; Hanrahan JP
Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
[TBL] [Abstract][Full Text] [Related]
13. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
Van Holsbeke C; De Backer J; Vos W; Marshall J
Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
[TBL] [Abstract][Full Text] [Related]
15. Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations.
Eibye K; Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Med Sci Sports Exerc; 2013 Jan; 45(1):16-22. PubMed ID: 22843108
[TBL] [Abstract][Full Text] [Related]
16. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
[TBL] [Abstract][Full Text] [Related]
17. Beta2-Agonist Doping Control and Optical Isomer Challenges.
Jacobson GA; Fawcett JP
Sports Med; 2016 Dec; 46(12):1787-1795. PubMed ID: 27164986
[TBL] [Abstract][Full Text] [Related]
18. Inhaled beta
Jeppesen JS; Jessen S; Thomassen M; Backer V; Bangsbo J; Hostrup M
Scand J Med Sci Sports; 2024 Jan; 34(1):e14500. PubMed ID: 37880916
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control.
Jessen S; Becker V; Rzeppa S; Backer V; Bengtsen KH; Hullstein I; Dehnes Y; Hostrup M
Drug Test Anal; 2021 Apr; 13(4):747-761. PubMed ID: 33210444
[TBL] [Abstract][Full Text] [Related]
20. Effect of formoterol, a long-acting β2-adrenergic agonist, on muscle strength and power output, metabolism, and fatigue during maximal sprinting in men.
Kalsen A; Hostrup M; Backer V; Bangsbo J
Am J Physiol Regul Integr Comp Physiol; 2016 Jun; 310(11):R1312-21. PubMed ID: 27147617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
